Featured News
Exploring ARIA in Alzheimer’s Disease Drug Discovery
Insights from Preclinical Imaging in the 5xFAD Mouse Model
Amyloid-related imaging abnormalities (ARIA) have been identified as a potential adverse side effect of anti-amyloid antibody therapies for Alzheimer’s disease (AD). The underlying cause of ARIA is thought to be antibody interactions with Aβ deposited in the walls of cerebral blood vessels. While ARIA can be asymptomatic, they can also manifest as headaches, confusion, or dizziness, or more severe outcomes such as brain swelling and/or brain bleeds.
ARIA covers two classes of magnetic resonance imaging (MRI) signal abnormalities – ARIA-E or ARIA-H.
ARIA-E (Edema/Effusion)
- Transient or progressive vasogenic edema or effusion, detected as hyperintense regions on T2-weighted MRI scans
- Thought to result from increased vascular permeability and fluid leakage into brain tissue and often linked to immune-mediated clearance of amyloid plaques
ARIA-H (Hemorrhage/Microbleeds)
- Encompasses cerebral microhemorrhages, larger hemorrhages, and superficial siderosis (iron deposits), detected as hypointense spots on T2* (T2-star) MRI because of iron sensitivity
- Likely due to vascular fragility and breakdown of the blood-brain barrier during amyloid clearance
Both ARIA-E and ARIA-H are clinically relevant because they represent potential safety concerns following treatment with anti-amyloid antibody therapies. Monitoring these events via MRI helps researchers and clinicians balance efficacy with safety in Alzheimer’s treatment strategies.
A recent study by researchers at Charles River and Alector LCC evaluated ARIA events in the 5xFAD mouse model during an 11-week treatment with the anti-Aβ antibody 3D6, a parent murine antibody of bapineuzumab targeting the N-terminal region of β-amyloid. The results, which were presented at SfN 2025, showed:
- High ARIA prevalence with 3D6 treatment: By 11 weeks, 77% of treated mice had ARIA-E (edema/effusion) and 69% showed ARIA-H (hemorrhage). In contrast, control mice displayed no ARIA lesions.
- Microbleed load increased significantly: Treated mice had an average of 52 microbleeds, compared to a minimal baseline in controls.
- Histopathology confirmed findings: Ex vivo analysis revealed perivascular microbleeds alongside Aβ plaques and microgliosis.
- MRI as a powerful evaluation tool: T2 and T2* MRI detected both transient and progressive ARIA-E lesions and hemorrhagic ARIA-H events, highlighting its sensitivity to vascular integrity and iron deposits.
These results underscore the importance of monitoring ARIA during anti-amyloid therapy development. Utilizing advanced imaging techniques and histological assessments in preclinical animal models will guide the development of safer, more effective treatment strategies for AD.